Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-substituted-hydrazinecarbothioamides. 2013

Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
1Department of Pharmaceutical Chemistry, KLE University's College of Pharmacy, Rajajinagar, Bangalore, 560010 Karnataka India.

Various 5-substituted-2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)hydrazinecarbothioamide (4a, b) and 5-substituted-2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-(phenyl-4-substituted)hydrazinecarbothioamide (5a-h) derivatives were synthesized. The compounds were screened for cytotoxicity against human HeLa and CEM T-lymphocytes as well as murine L1210 cells. The compounds were also screened for β-lactamase inhibitory activity, antiviral, antibacterial, and antifungal activity against various strains of microorganisms. Several of these compounds were endowed with low micromolar 50 %-cytostatic concentration (IC50) values, and some were virtually equally potent as melphalan. The most potent inhibitors against the murine leukemia cells (L1210) were also the most inhibitory against human T-lymphocyte (CEM) tumor cells. Derivative 2-(1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-N-(4-methoxyphenyl)hydrazinecarbothioamide 5c emerged as the most potent cytostatic compound among the tested compounds. Derivatives 4b, 5a, 5b, and 5d showed antiviral activity against HEL cell cultures (IC50 11-20 μM). Moderate antimicrobial activity was observed for all derivatives. The encouraging cytostatic and antiviral activity data provide an adequate rationale for further modification of these molecular scaffolds. Derivative 5c (1.9-4.4 μM) emerged as the most potent cytostatic compound among the tested compounds. Derivatives 4b, 5a, 5b, and 5d showed antiviral activity against HEL cell cultures (IC50 11-20 μM).

UI MeSH Term Description Entries

Related Publications

Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
July 2008, Biological & pharmaceutical bulletin,
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
May 2024, Bioorganic chemistry,
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
April 2012, Drug discoveries & therapeutics,
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
December 2011, Journal of enzyme inhibition and medicinal chemistry,
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
May 2008, Organic letters,
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
June 2018, Molecules (Basel, Switzerland),
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
April 2012, Acta crystallographica. Section E, Structure reports online,
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
December 2019, Archiv der Pharmazie,
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
September 2010, Bioorganic & medicinal chemistry letters,
Subhas S Karki, and Amol A Kulkarni, and Sujeet Kumar, and Suresh Kumar Veliyath, and Erik De Clercq, and Jan Balzarini
March 2015, European journal of medicinal chemistry,
Copied contents to your clipboard!